Technical Analysis for VRAX - Virax Biolabs Group Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.81 | 3.18% | 0.03 |
VRAX closed up 3.97 percent on Wednesday, May 15, 2024, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 3.18% | |
| Calm After Storm | Range Contraction | 3.18% | |
| NR7 | Range Contraction | 3.18% | |
| Upper Bollinger Band Walk | Strength | 3.18% | |
| Inside Day | Range Contraction | 3.18% | |
| Wide Bands | Range Expansion | 3.18% | |
| Gapped Up | Strength | 3.18% | |
| Fell Below 50 DMA | Bearish | 7.28% | |
| MACD Bullish Centerline Cross | Bullish | 7.28% | |
| Upper Bollinger Band Walk | Strength | 7.28% |
| Alert | Time |
|---|---|
| Possible NR7 | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 4 hours ago |
| Down 1% | about 4 hours ago |
| Upper Bollinger Band Resistance | about 4 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Hepatitis B Hepatitis Virus Malaria Viral Disease Herpes Herpes Simplex Monkeypox
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Hepatitis B Hepatitis Virus Malaria Viral Disease Herpes Herpes Simplex Monkeypox
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.445 |
| 52 Week Low | 0.6 |
| Average Volume | 28,344 |
| 200-Day Moving Average | 1.92 |
| 50-Day Moving Average | 0.76 |
| 20-Day Moving Average | 0.69 |
| 10-Day Moving Average | 0.72 |
| Average True Range | 0.08 |
| RSI (14) | 56.33 |
| ADX | 18.53 |
| +DI | 20.54 |
| -DI | 16.31 |
| Chandelier Exit (Long, 3 ATRs) | 0.60 |
| Chandelier Exit (Short, 3 ATRs) | 0.84 |
| Upper Bollinger Bands | 0.81 |
| Lower Bollinger Band | 0.57 |
| Percent B (%b) | 0.89 |
| BandWidth | 34.12 |
| MACD Line | 0.01 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0207 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.86 | ||||
| Resistance 3 (R3) | 0.86 | 0.83 | 0.85 | ||
| Resistance 2 (R2) | 0.83 | 0.82 | 0.83 | 0.84 | |
| Resistance 1 (R1) | 0.81 | 0.80 | 0.80 | 0.81 | 0.84 |
| Pivot Point | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 |
| Support 1 (S1) | 0.76 | 0.77 | 0.75 | 0.76 | 0.73 |
| Support 2 (S2) | 0.74 | 0.75 | 0.74 | 0.73 | |
| Support 3 (S3) | 0.71 | 0.74 | 0.72 | ||
| Support 4 (S4) | 0.71 |
